What the business is, and whether it's a good one at a fair price.
Operates as a pharmaceutical manufacturer with FY26 consolidated revenue of Rs 9,646.33 crore and consolidated net profit of Rs 1,183.78 crore. IPCA Laboratories sells into both domestic and export markets, with exports to over 100 countries accounting for 42% of revenue. On a standalone basis, FY26 total income was Rs 7,431 crore, up 10% from Rs 6,749 crore, with standalone net profit of Rs 1,132.5 crore and EBITDA of Rs 1,942 crore at a 26.1% margin. The business works with active pharmaceutical ingredients, currently sourcing fermentation-based APIs from Krebs Biochemicals, which the board approved merging into itself at a share-swap ratio of 7 IPCA shares for every 200 Krebs shares, with no cash consideration. The manufacturing operation runs with 16,052 permanent employees, with women at 20.59% in office roles. The largest cost lines are other operating expenses at 27.8% of revenue, raw materials at 24.3%, and employee costs at 22.4%, with depreciation at 4.3% and capex at 6.8% of revenue.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from IPCA LABORATORIES LTD's filed financials and exchange disclosures
IPCA LABORATORIES LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol IPCALAB.
Yes. Over the trailing twelve months IPCA LABORATORIES LTD reported a net profit of ₹1,375 Cr on revenue of ₹10,126 Cr.
Yes. The dividend yield is 0.11% at the current price. It paid out 4% of its profit as dividend in FY26.
No. Debt stands at 0.07× equity, and it carries net debt of ₹267 Cr. That is lower than 55% of its 171 Pharmaceuticals peers.
On trailing P/E, IPCA LABORATORIES LTD ranks 109 of 169 in Pharmaceuticals — cheaper than 36% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session IPCA LABORATORIES LTD moves 0.94% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by IPCA LABORATORIES LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
